Investors

News Releases

Date Title
May 18, 2018
Summary ToggleRXi Pharmaceuticals Announces Positive Results from Phase 2 Trial with Samcyprone™ for the Treatment of Common Warts
May 11, 2018
Summary ToggleRXi Pharmaceuticals Enters into Material Transfer Agreement with Iovance Biotherapeutics to Study its Self-Delivering RNAi Technology for the Advancement of Immuno-Oncology Therapeutics with Iovance's Tumor Infiltrating Lymphocytes (TILs) for Solid Tumors
May 10, 2018
Summary ToggleRXi Pharmaceuticals Reports First Quarter 2018 Financial Results and Recent Corporate Highlights
May 8, 2018
Summary ToggleRXi Pharmaceuticals Bolsters Strength of Dermatology Intellectual Property Estate Following Granting of Patent From USPTO
May 1, 2018
Summary ToggleRXi Pharmaceuticals Announces Presentation at the 2018 New York Oncology Investment Conference
Apr 24, 2018
Summary ToggleRXi Pharmaceuticals to Webcast First Quarter 2018 Financial Results on Thursday, May 10, 2018
Apr 16, 2018
Summary ToggleRXi Pharmaceuticals Announces Publication in Molecular Therapy on Self-Delivering RNAi (sd-rxRNA®) Targeting PD-1 in Adoptive Cell Therapy for the Treatment of Malignant Melanoma
Apr 11, 2018
Summary ToggleRXi Pharmaceuticals Announces Closing of $4.9 Million Registered Direct Offering
Apr 9, 2018
Summary ToggleRXi Pharmaceuticals Announces $4.9 Million Registered Direct Offering Priced At-the-Market
Apr 4, 2018
Summary ToggleRXi Pharmaceuticals to Present an Update on its Clinical and Cosmetic Dermatology Programs at the International Investigative Dermatology Conference
Displaying 1 - 10 of 205 results

Investors